Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 6/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4141975 | 0.91 | OPRM1 (0.38) | HRH3MCHR1KCNH2ALDH1A1 | |
| SCHEMBL4142343 | 0.91 | HRH3 (0.40) | HRH3BACE1FAAHKCNH2 | |
| SCHEMBL4129121 | 0.89 | HRH3 (0.39) | HRH3BACE1FAAHKCNH2 | |
| SCHEMBL4128725 | 0.87 | OPRM1 (0.40) | HRH3MCHR1KCNH2ALDH1A1 | |
| SCHEMBL4128728 | 0.87 | OPRM1 (0.40) | HRH3MCHR1KCNH2ALDH1A1 | |
| SCHEMBL4128730 | 0.87 | OPRM1 (0.40) | HRH3MCHR1KCNH2ALDH1A1 | |
| SCHEMBL4143136 | 0.87 | OPRM1 (0.40) | HRH3MCHR1KCNH2ALDH1A1 | |
| SCHEMBL4143141 | 0.87 | OPRM1 (0.40) | HRH3MCHR1KCNH2ALDH1A1 | |
| SCHEMBL4135788 | 0.86 | HRH3 (0.51) | HRH3BACE1FAAHCYP2D6ALDH1A1 | |
| SCHEMBL4136097 | 0.84 | TMEM97 (0.46) | HRH3BACE1HPGDMCHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885CHRNA7 55/4885BACE1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.